Gastroenterology
Volume 133, Issue 2 , Pages 393-402 , August 2007

Risk of Colorectal Cancer in Patients Prescribed Statins, Nonsteroidal Anti-Inflammatory Drugs, and Cyclooxygenase-2 Inhibitors: Nested Case-Control Study

  • Yana Vinogradova

      Affiliations

    • Division of Primary Care, University of Nottingham, Nottingham, United Kingdom
    • Corresponding Author InformationAddress requests for reprints to: Yana Vinogradova, MD, University Park, 13th Floor Tower Building, Nottingham NG7 2RD, United Kingdom. fax: (44) 11584 66904.
    • ,
  • Julia Hippisley–Cox

      Affiliations

    • Division of Primary Care, University of Nottingham, Nottingham, United Kingdom
    • ,
  • Carol Coupland

      Affiliations

    • Division of Primary Care, University of Nottingham, Nottingham, United Kingdom
    • ,
  • Richard F. Logan

      Affiliations

    • Division of Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom

Received 17 November 2006 ,Accepted 26 April 2007.

References 

  1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet. 2005;365:153–165
  2. Carlberg M, Dricu A, Blegen H, Wang M, Hjertman M, Zickert P, et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface (Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth). J Biol Chem. 1996;271:17453–17462
  3. Addeo R, Altucci L, Battista T, Bonapace IM, Cancemi M, Cicatiello L, et al. Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors. Biochem Biophys Res Commun. 1996;220:864–870
  4. Inano H, Suzuki K, Onoda M, Wakabayashi K. Anti-carcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats. Carcinogenesis. 1997;18:1723–1727
  5. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51:3602–3609
  6. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. ClinCancer Res. 1999;5:2223–2229
  7. Downs JR, Clearfield M, Weis S, Whitney E, Shipiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1349–1357
  8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007
  9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  10. Shepherd J, Blauw G, Murphy M, Bollen E, Buckley B, Cobbe S, et al. PROspective Study of Pravastatin in the Elderly at Risk (Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial). Lancet. 2002;360:1623–1630
  11. Dale K, Coleman C, Hentyan N, Kluger J, White C. Statins and cancer risk–a meta-analysis. JAMA. 2006;295:74–80
  12. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. Arch Intern Med. 2000;160:2363–2368
  13. Fris S, Poulsen AH, Johnson SP, McLaughlin JK, Fryzek JP, Dalton SO, et al. Cancer risk among statin users: A population-based cohort study. Int J Cancer. 2005;114:643–647
  14. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007;115:27–33
  15. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst. 2006;98:69–72
  16. Poynter JN, Gruber SB, Higgins PDR, Almog R, Bonner JD, Rennert HS, et al. Statins and risk of colorectal cancer. N Engl J Med. 2005;352:2184–2192
  17. Thun M, Henley S, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacological and clinical issues. J Natl Cancer Inst. 2002;94:252–266
  18. Garcia Rodriguez LA, Huerto-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12:88–93
  19. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102
  20. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–884
  21. Key Health Statistics from General Practice 1998: series MB6 (no 2). London, United Kingdom: Office for National Statistics; 2000;
  22. Hippisley-Cox J, Pringle M. Prevalence, care and outcomes for patients with diet controlled diabetes in general practice: cross sectional survey. Lancet. 2004;364:423–428
  23. Hammersley V, Hippisley-Cox J, Wilson A, Pringle M. A comparison of research general practices and their patients with other practices--cross sectional survey in Trent. Br J Gen Pract. 2002;52:463–468
  24. Hippisley-Cox J, Hammersley V, Pringle M, Coupland C, Crown N, Wright L. How useful are general practice databases for research? (Analysis of their accuracy and completeness in one research network). Health Informatics J. 2004;10:91–109
  25. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxgenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;331:1310–1316
  26. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330:1366–1374
  27. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ. 2005;330:1059–1063
  28. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet. 1997;349:525–528
  29. Eachus J, Williams M, Chan P, Smith GD, Grainge M, Donovan J, et al. Deprivation and cause specific morbidity: evidence from the Somerset and Avon survey of health. BMJ. 1996;312:287–292
  30. Cancer Statistics Registration 2003: series MB1 (no 34). London, United Kingdom: Office for National Statistics; 2005;
  31. Chan A, Giovannucci E, Meyerhardt J, Schernhammer E, Curhan G, Fuchs C. Long term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914–923
  32. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895
  33. Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar H-J. The risk of cancer in users of statins. J Clin Oncol. 2004;22:2388–2394
  34. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst. 2007;99:32–40
  35. Nazareth I, King M, Haines A, Ranger L, Myers S. Accuracy of diagnosis of psychosis in general practice computer system. BMJ. 1993;307:32–34
  36. Pollock A, Vickers N. Reducing DCO registrations through electronic matching of cancer registry data and routine hospital data. Br J Cancer. 2000;82:714–717

 Supported by the University of Nottingham. This work was undertaken during the course of normal academic duties. The QResearch database undertakes other work for a variety of government organisations. This work was not commissioned or funded by any external organisation.

 The study was initiated by JHC and designed by all the authors. The analysis was undertaken by YV and checked by JHC and CC. All authors contributed to the detailed analysis plan, interpretation of results, and drafting of the paper. YV and JHC are the guarantors of the study.

 All authors declare that they have no conflict of interest to disclose.

PII: S0016-5085(07)01005-0

doi: 10.1053/j.gastro.2007.05.023

Gastroenterology
Volume 133, Issue 2 , Pages 393-402 , August 2007

Article Tools

* Image Usage & Resolution